Progress at Work - The Impact of Adalimumab on Work Related Productivity in Patients With Rheumatoid Arthritis

1. Subjects with moderate to severe RA for whom the physician has decided to initiate treatment with adalimumab 2. Adult male or female ≥ 18 years old that has been newly prescribed adalimumab therapy according to the local product label and are with PROGRESS 3. Subjects should be evaluated for tuberculosis (TB) exposure/risk factors for active and latent TB 4. Subject is able to give written patient authorization and is willing to comply with the requirements of this study protocol.

1. Subject cannot or will not sign a patient authorization 2. Subject with a known hypersensitivity to Adalimumab, or any of its components 3. Presence of any condition that, in the opinion of the treating physician, prohibits the subject from participating in the study or obscures the assessment of the treatment of RA 4. Subjects currently participating in an investigational clinical trial 5. Subjects treated with \>1 prior biologic disease-modifying antirheumatic drugs (DMARDs) for RA. Any prior treatment with adalimumab is prohibited 6. Subjects previously treated with targeted synthetic disease modifying agent.